<DOC>
	<DOC>NCT01057693</DOC>
	<brief_summary>Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.</brief_summary>
	<brief_title>Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients must have painful diabetic peripheral neuropathy and be receiving treatment for this condition. Patients with other pain conditions cannot participate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Diabetic peripheral neuropathy</keyword>
	<keyword>Lyrica</keyword>
	<keyword>pregabalin</keyword>
	<keyword>pain</keyword>
</DOC>